Ardelyx, Inc.
Ardelyx, Inc. is listed today as Ardelyx, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2016 | $110 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Jun 2015 | $78 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Jun 2011 | $18 M | No. 2 | $10 to $50 million | equity | SEC | |
| Nov 2010 | $5 M | No. 1 | $2 to $10 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Ardelyx, Inc., its revenue in fiscal 2025 came from these product and service lines: IBSRELA $274.21 million (67%), XPHOZAH $103.60 million (25%), Other cost of revenue $29.51 million (7%), Product supply revenue $15.88 million (4%), Non-cash royalty revenue related to the sale of future royalties $8.54 million (2%).
Annual report (SEC XBRL) · Dec 2025
Ardelyx, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2016).
SEC Form D · Aug 2016
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Aug 2016
Products and services#
No products or services of Ardelyx, Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| CMEA Ventures VII LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Cmea Ventures VII (parallel) LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Nea 12 GP, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| NEA Partners 12, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| New Enterprise Associates 12, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Peter G. Schultz | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.
Largest shareholders today
Institutions holding Ardelyx, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$97 M11.28%
- Rubric Capital Management LP$48 M5.53%
- Millennium Management LLC$46 M5.35%
- State Street Corp$45 M5.27%
- Vanguard Capital Management LLC$36 M4.16%
- Tang Capital Management LLC$31 M3.60%
- Nomura Asset Management International Inc.$30 M3.52%
- Vanguard Portfolio Management LLC$27 M3.17%
- Geode Capital Management, LLC$21 M2.47%
- Two Sigma Investments, LP$19 M2.16%
- Caption Management, LLC$14 M1.64%
- Invesco Ltd.$12 M1.35%
- Goldman Sachs Group Inc$11 M1.29%
- Nuveen, LLC$10 M1.15%
- Morgan Stanley$9 M1.03%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Rosenbaum | Executive officer | Aug 2016 |
| Elizabeth Grammer | Executive officer | Aug 2016 |
| Jeff Jacobs | Executive officer | Aug 2016 |
| Jeremy Caldwell | Executive officer | Aug 2016 |
| Mark Kaufmann | Executive officer | Aug 2016 |
| Michael Raab | Executive officer | Aug 2016 |
| Paul Korner | Executive officer | Aug 2016 |
| David G. Rosenbaum | Executive officer | Jun 2015 |
| Elizabeth G. Grammer | Executive officer | Jun 2015 |
| Jeremy G. Caldwell | Executive officer | Jun 2015 |
| Mark G. Kaufmann | Executive officer | Jun 2015 |
| Dominique Charmot | Chief Scientific Officer | Jul 2011 |
| Annalisa Jenkins | Director | Aug 2016 |
| David Mott | Director | Aug 2016 |
| Gordon Ringold | Director | Aug 2016 |
| Michael Raab | Director | Aug 2016 |
| Richard Rodgers | Director | Aug 2016 |
| Robert Bazemore | Director | Aug 2016 |
| William Bertrand, Jr. | Director | Aug 2016 |
| Annalisa G. Jenkins | Director | Jun 2015 |
| Gordon G. Ringold | Director | Jun 2015 |
| Peter G. Schultz | Director | Jun 2015 |
| Richard G. Rodgers | Director | Jun 2015 |
| David Collier | Director | Jul 2011 |
| Dominique Charmot | Chief Scientific Officer | Jul 2011 |
| Jean Frechet | Director | Jul 2011 |
| Peter Schultz | Director | Jul 2011 |
About
Company in Fremont, United States.
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.